Sam Fazeli

I know that I'm probably the last man standing here and they are the last company standing pretty much.

What's yours?

Yeah, I agree.

I mean, we've got some of the more clever, well, not more clever, also interesting antibody molecule conjugates coming up, right?

People who have just been learning about folks using an anti-EGFR, for instance, or an anti-HER2 to bring a kinase inhibitor.

to the milieu, to the cells, or RNA modulators, siRNA, etc.

So that's going to be really exciting.

I just hope that the world is there and ready to remember that these drugs, at the end of the day, need to sell

and make some money for the companies that are developing them otherwise what's the point uh last couple of minutes um mna 2026 five turned out to be okay or good i would say in terms of pharma buying biotechs pharma biotechs buying biotechs genmab and and um and mares for example what's your feel for 26 do you feel the momentum in the second half of the year is going to be kept

Is that what you're hearing?

I mean, I've got friends on the sales side.

I don't know if you follow the Biotech Hangout ever that I get involved with on Fridays sometimes.

Southside friends out of the US, Lear Inc.

friends, or Cantor, Karen, Jeffrey's used to come along, but he's moved.

And I think we had a range of something between 15 to 50 companies potentially IPOing in 2026.

And are you optimistic that we're going to be able to see some of this momentum in the follow-on market, potentially wash through to IPOs, essentially, eventually in 2026?

Antoine, again, it just reminded me how wonderful it is to talk to you either on a panel or together like this.

We really have to make sure that this happens a little bit more often.

Whether it's a podcast or whether we just meet each other at your wonderful offices where I can see behind you.

So thank you for your time.